Condition
Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (1)
P 2 (1)
Trial Status
Not Yet Recruiting2
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07552402Not ApplicableNot Yet RecruitingPrimary
Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
NCT07492615Phase 2RecruitingPrimary
A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma
NCT07358884Phase 1Not Yet Recruiting
First in Human Study of QLS5316 in Solid Tumors
Showing all 3 trials